Company Overview and News
TORONTO, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Compass Gold Corp. (TSX-V:CVB) (Compass or the Company) is pleased to provide an update on the now completed priority shallow soil geochemical survey program over the Kourou and Tiélouléna exploration permits on its Sikasso Property in Southern Mali.
COGDF HUMRF EDVVF EDVMF EVR COGDD CVB.H HUM EDV
BAMAKO, Oct 5 (Reuters) - Industrial gold production in Mali, Africa’s third biggest producer, is still expected to rise almost 21 percent to 60 tonnes this year, a government official told Reuters on Friday, despite slightly lower than expected output so far.
AULGF RSG RMGGY HUMRF RGORF RMGGF AU AGG GOLD RRS HUM GOLD
Silver is cheap. In fact, it has been sub $16 since late June and is currently below $15. It is so cheap, that bullion banks are long silver for the first time in 24 years! Follow this link for confirmation.
NGD ALO HUMRF NGDAF HL ARNGF NGD HTXFF HUM AR
Last time I wrote about Hummingbird Resources (OTCPK:HUMRF) was on May 10 and since then the shares of the company have lost almost 19% of their price on the London Stock Exchange. Sure, the price of gold is down more than $100 per ounce since then but the selloff seems unjustified considering the amount of free cash flow that the company is generating and the excellent production results for the second quarter of 2018.
D BHLL HUMRF LNSTY HUM
TORONTO, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Bunker Hill Mining Corporation (the “Company” or “Bunker”) (CSE:BNKR) is pleased to announce that two key investors in the Company have agreed to (separately) increase their investments, for gross proceeds of CAD$1,379,304. Firstly, the investment by an arm's length investor (Hummingbird Resources PLC (“Hummingbird”) announced June 19, 2018 will increase from USD$1,500,000 ("Initial Amount") to USD$2,000,000 ("Principal Amount") by an investment of USD$500,000 ("Additional Amount").
HUMRF BHLL HUM
Ausdrill’s shares have dropped by a quarter this week due to ongoing contract negotiations regarding Mineral Resources’ Wodgina project, as well as delays arising from the rock fall at the Kalgoorlie Super Pit in the Goldfields, both in Western Australia.
HUMRF MALRY MALRF MIN HUM
2018-06-01 seekingalpha - 2
Below is a list of 10 quality gold producers. I have selected them as the best risk/reward leveraged gold stocks. All of these should outperform the price of gold if it rises. In fact, I expect all of these stocks to double in value if gold reaches $1,600. These are the stocks that you want to own if you are looking for high returns if gold prices start trending. Also, if you are looking for a way to hedge against a market crash, then these stocks offer a potential hedge.
NGDAF ARNGF NGD TGD MUX.RTWI HUMRF DGC EDVVF PMNXF GCM.WT.A PRU MUX AR HTXFF HUM EDV RPM NGD ALO MUX TPWRF WDO EDVMF RPMGD DRGDF RPMGF PRU TPRFF GCM TMM EVR WDOFF
Ausdrill has confirmed that employees from subsidiary, African Mining Services, are safe following a security incident at its contract with Hummingbird Resources at the Yanfolila gold operation in Mali.
Hummingbird Resources (OTCPK:HUMRF) has come a very long way since I covered the company in SA in November 2017. It poured first gold at its Yanfolila gold mine in Mali at the end of December 2017, and it achieved commercial production as of 1 April 2018. What’s remarkable in this case is that the project was delivered on time and on budget, which is pretty rare in the gold mining space.
AGGFF HUMRF NCU EDVVF EDVMF LNSTY EVR AGG NEVDF HUM EDV
BAMAKO (Reuters) - Mali’s government is negotiating with mining companies to draft a new mining code but will move to implement a new law unilaterally if no compromise is reached, the West African country’s economy minister said on Friday.
AULGF HUMRF AU AGG HUM
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to LSE:HUM / HUMMINGBIRD RESOURCES PLC on message board site Silicon Investor.